For each of us, our unique biology is changing moment to moment. Yet, we only measure our biological state intermittently, almost exclusively in the confines of clinics, hospitals and doctor’s offices. This lack of scalable, longitudinal, on-demand data results in time and money wasted on suboptimal diagnostics, drugs, and failed clinical trials due to mismatches between treatments and human biology.

ImYoo was founded to fill this data gap with a patient-enabled biodiscovery platform that generates scaleable, high fidelity, longitudinal data – the essential components for training machine learning models that can predict treatments from biology, enabling more precise and targeted medicine. Their innovative approach brings single-cell multiomic analysis to small blood volumes self-collected at home. Their initial customer base includes discovery teams at biopharma & clinics exploring auto-immune disease diagnosis, progression, therapy efficacy and drug discovery.

List of speakers:

  • Tatyana Dobreva, CEO and Co-founder, Ph.D., Caltech, Medical Engineering
  • David Brown, CTO and Co-founder, Ph. D., Caltech, Computation & Neural Systems
  • David Fleck, Founder and Managing Partner, Freeflow Ventures
  • Kevin Barrett, Managing Partner, Freeflow Ventures